Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model

Journal of Nuclear Medicine

Volumn 40, Issue 1, 1999, Pages 177-183

  Lewis, Jason S ^b   McCarthy, Deborah W ^b   McCarthy, Timothy J ^b   Fujibayashi, Yasuhisa ^b   Welch, Michael J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

60Cu; 64Cu; ATSM; EMT6; Hypoxia

Indexed keywords

COPPER 64; COPPER DERIVATIVE; COPPER DIACETYL BIS(N4 MEHTHYLTHIOSEMICARBAZONE); UNCLASSIFIED DRUG; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; COPPER (II) DIACETYL DI(N(4) METHYLTHIOSEMICARBAZONE); COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); COPPER PYRUVALDEHYDE BIS(N(4) METHYLTHIOSEMICARBAZONE) COMPLEX; COPPER PYRUVALDEHYDE BIS(N(4)-METHYLTHIOSEMICARBAZONE) COMPLEX; DIAGNOSTIC AGENT; DRUG DERIVATIVE; MISONIDAZOLE; ORGANOMETALLIC COMPOUND; OXYGEN; THIOSEMICARBAZONE DERIVATIVE;

ANIMAL MODEL; ARTICLE; DIAGNOSTIC VALUE; HYPOXIA; ISCHEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; TUMOR BLOOD FLOW; TUMOR CELL; ANIMAL; AUTORADIOGRAPHY; BAGG ALBINO MOUSE; CELL CULTURE; CELL HYPOXIA; COMPARATIVE STUDY; DRUG SCREENING; EXPERIMENTAL NEOPLASM; FEMALE; METABOLISM; TISSUE DISTRIBUTION;

ANIMALS; AUTORADIOGRAPHY; CELL HYPOXIA; DRUG EVALUATION, PRECLINICAL; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MISONIDAZOLE; ORGANOMETALLIC COMPOUNDS; OXYGEN; THIOSEMICARBAZONES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0032587218     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Coleman CN. Hypoxia in tumors: a paradigm for the approach to biochemical and physiological heterogeneity. J Natl Cancer Inst. 1988;80:310-317.
2. Peters LJ, Withers HR, Thames HD, Fletcher GH. Keynote address - the problem: tumor radioresistance in clinical radiotherapy. Int J Radiat Oncol Biol Phys. 1982;8:101-108.
3. Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Br J Radiol. 1987;26:638-648.
4. Rockwell S, Keyes SR, Sartorelli AC. Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiat Res. 1988;116:100-113.
5. Rockwell S. Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cells in vitro. Int J Cancer. 1986;38:229-235.
6. 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer. 1992;65:90-95.
7. Grosher D, McEwan AJB, Parliament MB, et al. Imaging tumor hypoxia and tumor perfusion. J Nucl Med. 1993;34:885-888.
8. Ng CK, Sinusas AJ, Zaret B, Souter R. Kinetic analysis of technetium-99m-labeled nitromidazole (BMS181321) as a tracer of myocardial hypoxia. Circulation. 1995;92:1261-1268.
9. Rumsey WL, Patel B, Linder K. Effect of graded hypoxia in retention of technetium-99m-nitroheterocycle in perfused rat hearts. J Nucl Med. 1995;36:632-636.
10. Martin GV, Biskupiak JE, Caldwell JH, Rasey JS, Krohn KA. Characterization of iodovinylmisonidazole as a marker for myocardial hypoxia. J Nucl Med. 1993;34:918-924.
11. Ballinger JR, Wan Min Kee J, Rauth AM. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med. 1996;37:1023-1031.
12. Cook GJR, Houston S, Barrington SF, Fogelman I. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med. 1998;39:99-103.
13. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol. 1996;23:957-980.
14. Taniuchi H, Fujibayashi Y, Yonekura Y, Konishi J, Yokoyama A. Hyperfixation of copper-62-PTSM in rat brain after transient global ischemia. J Nucl Med. 1997;38:1130-1134.
15. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155-1160.
16. Takahashi N, Fujibayashi Y, Yonekura Y, et al. Evaluation of copper-62 ATSM in patients with lung cancer as a hypoxic tissue tracer [Abstract]. J Nucl Med. 1998;39:53P.
17. 64Cu using a biomedical cyclotron. Nucl Med Biol. 1997;24:35-43.
18. Bass LA, McCarthy DW, Jones LA, et al. High purity production and potential applications of copper-60 and copper-61. J Label Comp Radiopharm. 1997;40:325-327.
19. 18F]fluoromisonidazole. Appl Radiat Isot. 1993;44:1129-1132.
20. 64Cu-ATSM a hypoxia imaging agent and C-11-acetate in an acute myocardial infarction model: ex vivo imaging in rats. Nucl Med Biol. in press.
21. Young H, Carnochan P, Zweit J, Babich J, Cherry S, Ott R. Evaluation of copper(II)-pyruvaldehyde bis(N-4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model. J Nucl Med. 1994;21:336-341.
22. Lewis JS. Phosphine ligands as a basis for copper radiopharmaceutical chemistry. [PhD thesis]. Canterbury, United Kingdom: The University of Kent at Canterbury; 1996.
23. Dearling JLD, Lewis JS, Mullen GED, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: Selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med. 1998;25:788-792.
24. 4-methylthiosemicarbazone). Nucl Med Biol. 1987;14:59-61.
25. 4-methylthiosemicarbazone)copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. J Nucl Med. 1990;31:1989-1996.
26. Mathias CJ, Welch MJ, Perry DJ, et al. Investigation of copper-PTSM as a PET tracer for tumor blood flow. Nucl Med Biol. 1991;18:807-811.
27. 4-methylthiosemicarbazone) (Cu-PTSM), a metal complex with selective NADH-dependent reduction by complex I in brain mitochondria: a potential radiopharmaceutical for mitochondria-functional imaging with positron emission tomography. Biol Pharm Bull. 1995;18:1126-1129.
28. Koh W-J, Rasey JS, Evans ML. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199-212.
29. Shelton ME, Dence C, Hwang D-R, Welch MJ. Myocardial kinetics of fluorine-18 misonidazole: a marker of hypoxic myocardium. J Nucl Med. 1989;30:351-358.
30. Martin GV, Caldwell JH, Graham MM, et al. Non-invasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med. 1992;33:2202-2208.
31. Rockwell S. In vivo-in vitro tumor systems: new models for studying the response of tumors to therapy. Lab Animal Sci. 1977;27:831-851.
32. Shibamoto Y, Nishimoto S, Mi F, Sasai K, Kagiya T, Abe M. Evaluation of various types of new hypoxic cell sensitizers using the EMT6 single cell-spheroid-solid tumor system. Int J Radiat Biol. 1987;52:347-357.
33. Franko AJ. Hypoxic fraction and binding of misonidazole in EMT6/Ed multicellular tumor spheroids. Radiat Res. 1985;103:89-97.
34. Moulder JE, Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys. 1984;10:695-712.
35. Rasey JS, Wui-Jin K, Grierson JR, Grunbaum Z, Krohn KA. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys. 1989;17:985-991.
36. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiation Res. 1990;122: 301-308.
37. Minkel DT, Saryan LA, Petering DH. Structure-function correlations in the reaction of bis(thiosemicarbazonato) copper(II) complexes with Ehrlich ascites tumor cells. Cancer Res. 1978;38:124-129.
38. McGilvery RW, Goldstein GW. Oxidations and phosphorylations. In: McGilvery RW, ed. Biochemistry, A Functional Approach. 3rd ed. Philadelphia, PA: WB Saunders; 1983:390-420.
39. Barlow CH, Harken AH, Chance B. Evaluation of cardiac ischemia by NADH fluorescence photography. Ann Surg. 1977;186:737-740.
40. Barnhart-Bott A, Green MA. The effects of glutathione depletion on the biodistribution of Cu(PTSM) in rats. Nucl Med Biol. 1991;18:865-869.
41. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 1995;22:265-280.